39/73
  • Pages
  • Editions
01 Cover
02 Welcome Letter / Sections
03 Article & Interview Directory
04 Section 1: Introduction
05 Introduction to US Life Sciences
06 Janssen Pharmaceuticals Interview
07 Investment Climate
08 MPM Capital Interview
09 Signet Healthcare Partners Interview
10 Xontogeny Interview
11 Insights from EisnerAmper
12 The Life Sciences Regulatory Climate
13 Buchanan Ingersoll & Rooney PC Interview
14 PhRMA Interview
15 PBOA Interview
16 Ernst & Young LLP Interview
17 LaVoieHealthScience Interview
18 Section 2: Introducing the Hubs
19 East Coast
20 BioNJ Interview
21 MassBio Interview
22 Pennsylvania Biotechnology Center Interview
23 West Coast
24 Biocom California Interview
25 QB3-Berkeley Interview
26 Section 3: Drug Discovery and Development
27 Therapeutic Fields On Fire
28 Insmed Interview
29 Mammoth Biosciences Interview
30 Innovations Enhancing the Patient Experience
31 Arcturus Therapeutics Interview
32 Karius Interview
33 Expert Insights: Targeted Therapeutics
34 First Wave BioPharma Interview
35 Aphios Corporation Interview
36 Section 4: Contract Manufacturing and Chemicals
37 A Shifting Landscape
38 Syngene International Interview
39 Cambrex Interview
40 Lubrizol Life Science Interview
41 Aenova Group Interview
42 Keeping Up With Demands
43 Cureline Interview
44 Interview: Murli Krishna Pharma
45 PsychoGenics Interview
46 Expert Insights: Innovative Technologies
47 AMPAC Fine Chemicals Interview
48 TCG Lifesciences Interview
49 CordenPharma Interview
50 Quotient Sciences Interview
51 A Post-Pandemic World
52 New Vision Pharmaceuticals Interview
53 Adare Pharma Solutions Interview
54 Ascendia Pharmaceuticals Interview
55 Chemicals Producers and Distributors
56 Brenntag North America Interview
57 BASF Pharma Solutions Interview
58 Section 5: Technology Services
59 Life Sciences Go Digital
60 RxS Interview
61 Insights from Markem-Imaje
62 AiCure Interview
63 WhizAI Interview
64 Section 6: Company Profiles
65 Brenntag Company Profile
66 Adare Pharma Solutions Company Profile
67 Quotient Sciences Company Profile
68 SK pharmteco Company Profile
69 AiCure Company Profile
70 Markem-Imaje Company Profile
71 TCG Lifesciences Company Profile
72 Murli Krishna Pharma Company Profile
73 Credits

Thomas Loewald, CEO,

CAMBREX

"The growth in large molecules has been extremely impressive, and we are tapping into this market."

Could you provide an overview of Cambrex's core services?

Cambrex is a global CDMO that provides drug substance, drug product, and analytical services across the entire drug lifecycle, helping our customers develop and deliver life-improving therapeutics. In 2021, we celebrated our 40th year with a growing team of over 2,200 employees serving global clients from 12 facilities across North America and Europe.

Cambrex offers clients the ability to work with us from the preclinical stage through the product lifecycle into commercialization. For drug substance we offer a range of technology enabling us to serve most small molecules, including continuous flow, biocatalysis, controlled substances, highly potent products, and a range of production scales from kilo labs to 16,000 liters. We offer a wide range of dosage forms including tablets, capsules, extended-release formulations, liquids, semi-solids, suppositories and pediatric formulations.

How important are small molecule and large molecule therapeutics to Cambrex?

Historically, our core business has been developing and manufacturing small molecule therapeutics. Small and mid-size biotech and pharma companies are leading the way, owning a growing share of the development pipeline compared to their big pharma peers. Additionally, orphan drug approvals account for an increasing proportion of new approvals. We have invested over US$100 million in capacity expansion across clinical and commercial production to meet demand.

Newer to Cambrex is the large molecule space, where we have a rapidly growing analytical business serving biopharmaceutical products and have invested in labs, equipment and talent to support increasing demand. The large molecule market is growing at an even faster rate than the small molecule side, and we see strong demand for analytical services supporting the development and manufacturing of biopharmaceutical products. It was a natural step for us to serve biotherapeutics as we were driven by previous customers requesting we broaden our range of analytical services. We also saw significant overlap in the instrumentation used to support small molecules.

How does Cambrex’s "reverse engineering methodology" in drug development ensure on-time product delivery amid supply chain disruptions?

Using the reverse engineering approach our teams plan projects from the end to the beginning by looking for critical path materials or activities, proactively moving those items off the critical path, then repeating. While this does not make Cambrex completely immune to supply chain disruptions, it ensures the company has the most robust project plan possible before the first raw materials are ordered.

What key trends do you see presently driving the life sciences space, and how do these inform your business strategy?

The first trend is the ownership of the development pipeline and commercialization of new products shifting from large pharma to small and mid-size companies. This has driven an increased level of outsourcing, as smaller companies tend to need more support along the development journey and often own no commercial-scale manufacturing assets. CDMO outsourcing rates are still relatively low, roughly 40-50% depending on the service, and we expect that rate to continue to grow.

The second trend is the emergence of more targeted, personalized medicine with orphan drug approvals now exceeding non-orphan drug approvals. This has two impacts on our business. First, we need more flexible manufacturing assets to support a wide range of batch sizes and the technologies to cover the development of those molecules. For this reason, we are investing in small-scale commercial assets and highly potent technology at our High Point, NC facility. Second, smaller batch sizes lead to a higher level of demand for analytical resources relative to manufacturing assets, as each batch must be tested the same way, whether it is enough material to treat 10 patients or 10,000 patients. We have seen an industry-wide shortage in analytical resources, creating a very strong demand in our analytical service portfolio.

Finally, we have seen robust growth across small and large molecules, but higher growth in new modalities such as cell and gene therapy. The growth in large molecules has been extremely impressive, and we are tapping into this market.

What is Cambrex’s business development strategy for the next few years?

Cambrex has a track record of above-market growth over the past 10 years, and our goal is to continue that trend. We have great organic growth opportunities and will continue to invest heavily in our core business. On the inorganic side, our priorities include adding scale to our core business, complementary technologies that would allow us to serve a broader cross-section of our customers' pipelines, and potentially new services that would increase our exposure to the large molecule market.

Next:

Interview: Lubrizol Life Science